2025 RNDS | What is Tolerization in NMO and MOGAD? @wearesrna
2025 RNDS | What is Tolerization in NMO and MOGAD?  @wearesrna
Uploaded December 2025 | Updated November 2026, 1 day ago
In this engaging talk at the 2025 Virtual RNDS, Dr. Michael Yeaman from UCLA explored the concept of tolerization in NMOSD and MOGAD, offering insights into its potential for restoring immune tolerance and improving patient outcomes. He reviewed the pros and cons of current immune-modifying therapies and elucidated the fascinating science behind immune tolerance, highlighting why NMOSD and MOGAD are ideal models for tolerization research. Dr. Yeaman also discussed various ground-breaking tolerization approaches, including CAR T therapies, dendritic cell vaccines, and inverse vaccines, detailing their mechanisms and potential long-term benefits. The talk concluded with fascinating updates on recent clinical trials and a hopeful outlook on the future of tolerization technologies in treating autoimmune diseases.

00:00 Introduction
00:34 Overview of Tolerization in NMOSD and MOGAD
01:59 Pros and Cons of Current Autoimmune Therapies
05:24 Understanding Immune Tolerance
07:58 Mechanisms of Immune Tolerance and Loss
14:42 NMOSD and MOGAD as Models for Tolerization
18:36 Immune Tolerization: Goals and Methods
31:49 Clinical Trials and Future Prospects
44:09 Questions from the community
2025 RNDS | What is Tolerization in NMO and MOGAD?2024 Stronger Together | Creative Connections: 30-Word StoriesAsk the Expert 1411. All About the Rare Neuroimmune Disorders Symposium2025 RNDS | Disability Pride:  Reframing Disability2026 RNDS | Diagnostic Workup Masterclass: Medical Professionals Share Insight on Tests and Criteria2024 RNDS | What’s my Diagnosis? Community Members Share their Diagnostic JourneyAsk the Expert 1403. Open Q&A on MOG Antibody Disease (MOGAD)2025 RNDS en Español | Trastornos neuroinmunes poco frecuentes: EMAD y MFA2023 RNDS | Open Q&A SessionCommunity Meets Clinic 305. Dr. Elena GrebenciucovaCommunity Meets Clinic 307. Dr. Melissa WrightShaping the Future of Rare Neuroimmune Disorders: The Exponential Impact of the Lubin Fellowship
SRNA |

2025 RNDS | What is Tolerization in NMO and MOGAD?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER